{"filing":{"accession_number":"0001193125-26-333820","cik":"0001609809","ticker":"MCRB","company_name":"Seres Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-05","report_date":"2026-08-05","primary_document":"d124829d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312526333820/d124829d8k.htm"},"events":[{"id":24476,"run_id":22179,"accession_number":"0001193125-26-333820","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Seres Therapeutics announced its second quarter 2026 financial results on August 5, 2026, disclosing net income of $4.6 million (versus a net loss of $19.9 million in Q2 2025), R\u0026D expenses of $9.1 million, G\u0026A expenses of $7.1 million, and cash position of $15.6 million as of June 30, 2026. The press release (Exhibit 99.1) is the standard earnings announcement format with detailed financial results and operational updates, filed under Item 2.02 (Results of Operations and Financial Condition).","company_name":"Seres Therapeutics, Inc.","ticker":"MCRB","filing_date":"2026-08-05","form":"8-K","submitted_at":null,"items":[{"id":25038,"accession_number":"0001193125-26-333820","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Seres Therapeutics announced its second quarter 2026 financial results on August 5, 2026, disclosing net income of $4.6 million (versus a net loss of $19.9 million in Q2 2025), R\u0026D expenses of $9.1 million, G\u0026A expenses of $7.1 million, and cash position of $15.6 million as of June 30, 2026. The press release (Exhibit 99.1) is the standard earnings announcement format with detailed financial results and operational updates, filed under Item 2.02 (Results of Operations and Financial Condition).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-06T02:38:58.967423+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":25038,"accession_number":"0001193125-26-333820","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Seres Therapeutics announced its second quarter 2026 financial results on August 5, 2026, disclosing net income of $4.6 million (versus a net loss of $19.9 million in Q2 2025), R\u0026D expenses of $9.1 million, G\u0026A expenses of $7.1 million, and cash position of $15.6 million as of June 30, 2026. The press release (Exhibit 99.1) is the standard earnings announcement format with detailed financial results and operational updates, filed under Item 2.02 (Results of Operations and Financial Condition).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-06T02:38:58.967423+00:00","company_name":"Seres Therapeutics, Inc.","ticker":"MCRB","filing_date":"2026-08-05"}]}